Search - tctmd.com

Displaying 61 - 73 of 73

Sort: Relevancy | Date

News Daily News

TCTMD’s Top 10 Most Popular Stories for July 2019

Shelley Wood

July 31, 2019

News Daily News

Thwarted Access to PCSK9 Inhibitors Linked to Greater Risk of Major CV Events

Marcus A. Banks

July 25, 2019

News Conference News SCCT 2019

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Yael L. Maxwell

July 15, 2019

News Industry News

Concept Medical Inc. Granted "Breakthrough Device Designation" From FDA for Its MagicTouch Sirolimus Coated Balloon

May 02, 2019

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Industry News

Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes

March 23, 2018

News Daily News

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

Yael L. Maxwell

January 24, 2018

News Daily News

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Yael L. Maxwell

October 30, 2017

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

News Daily News

Trump’s Unexpected Win Met With Everything From Shock to Optimism Among US Cardiologists

Todd Neale

November 09, 2016

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

News Daily News

Washington State Sees Increase in Appropriate PCI After AUC Introduction

L.A. McKeown

June 08, 2015

Advertisement

TCTMD’s Top 10 Most Popular Stories for July 2019

Thwarted Access to PCSK9 Inhibitors Linked to Greater Risk of Major CV Events

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Concept Medical Inc. Granted "Breakthrough Device Designation" From FDA for Its MagicTouch Sirolimus Coated Balloon

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Trump’s Unexpected Win Met With Everything From Shock to Optimism Among US Cardiologists

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

Washington State Sees Increase in Appropriate PCI After AUC Introduction

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content